These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7583868)

  • 1. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge.
    Ciprandi G; Buscaglia S; Pronzato C; Benvenuti C; Cavalli E; Bruzzone F; Canonica GW
    Ann Allergy Asthma Immunol; 1995 Nov; 75(5):446-52. PubMed ID: 7583868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
    Ciprandi G; Buscaglia S; Catrullo A; Pesce G; Fiorino N; Montagna P; Bagnasco M; Canonica GW
    Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.
    Ciprandi G; Cosentino C; Milanese M; Tosca MA
    Ann Allergy Asthma Immunol; 2003 Apr; 90(4):434-8. PubMed ID: 12722967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge.
    Ciprandi G; Buscaglia S; Pesce G; Passalacqua G; Rihoux JP; Bagnasco M; Canonica GW
    J Allergy Clin Immunol; 1995 Feb; 95(2):612-21. PubMed ID: 7531732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro.
    Buscaglia S; Paolieri F; Catrullo A; Fiorino N; Riccio AM; Pesce G; Montagna P; Bagnasco M; Ciprandi G; Canonica GW
    Clin Exp Allergy; 1996 Oct; 26(10):1188-96. PubMed ID: 8911706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
    Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
    J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mizolastine and fexofenadine modulate cytokine pattern after nasal allergen challenge.
    Ciprandi G; Cirillo I; Vizzaccaro A
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):146-50. PubMed ID: 15180356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV; Udell IJ
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB; Ferzola NJ; McWhirter CL; Crampton HJ
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: effects of single allergen challenge.
    Holm A; Dijkstra M; Kleinjan A; Severijnen LA; Boks S; Mulder P; Fokkens W
    J Allergy Clin Immunol; 2001 Apr; 107(4):627-33. PubMed ID: 11295650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deflazacort protects against late-phase but not early-phase reactions induced by the allergen-specific conjunctival provocation test.
    Ciprandi G; Buscaglia S; Pesce GP; Iudice A; Bagnasco M; Canonica GW
    Allergy; 1993 Aug; 48(6):421-30. PubMed ID: 7902021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication.
    Akerlund A; Andersson M; Leflein J; Lildholdt T; Mygind N
    J Allergy Clin Immunol; 2005 Mar; 115(3 Suppl 1):S460-82. PubMed ID: 15746883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
    van Schalkwyk E; Strydom K; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbröker D; Bardin PG
    J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lodoxamide versus spaglumic acid: a comparative double-blind trial on patients suffering from seasonal allergic conjunctivitis induced by Parietaria pollen.
    Purello D'Ambrosio F; Gangemi S; Ricciardi L; Cuzzocrea S; Di Lorenzo G
    Allergol Immunopathol (Madr); 1997; 25(5):233-7. PubMed ID: 9395007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G; Ajayi Y; Stern ME; Calder VL
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
    Louw C; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbroker D; Bardin PG
    Respiration; 2007; 74(4):411-7. PubMed ID: 16954654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.